Effects of glutamate positive modulators on cognitive deficits in schizophrenia: A systematic review and meta-Analysis of double-blind randomized controlled trials

Molecular Psychiatry

Volumn 20, Issue 10, 2015, Pages 1151-1160

  Iwata, Y ^a,b,c   Nakajima, S ^a,b,c   Suzuki, T ^c   Keefe, R S E ^d   Plitman, E ^a,e   Chung, J K ^a,e   Caravaggio, F ^a,e   Mimura, M ^c   Graff Guerrero, A ^a,b   Uchida, H ^a,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c KEIO UNIVERSITY   (Japan)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; BENZOIC ACID; CARNOSINE; CYCLOSERINE; DEXTRO SERINE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR AGONIST; GLUTAMIC ACID; GLUTAMINE; GLYCINE; GLYCINE TRANSPORTER 1; IONOTROPIC RECEPTOR; KAINIC ACID; KYNURENINE AMINOTRANSFERASE; METABOTROPIC RECEPTOR; MINOCYCLINE; N ACETYLASPARTYLGLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NOOTROPIC AGENT; ORG 25935; PLACEBO; PREGNENOLONE; SARCOSINE; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR AFFECTING AGENT;

COGNITION; COGNITIVE DEFECT; DRUG EFFICACY; EMBASE; GLUTAMATERGIC TRANSMISSION; HUMAN; MEDLINE; MENTAL PATIENT; META ANALYSIS; NEUROPHARMACOLOGY; NEUROTRANSMISSION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; COGNITION DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; METABOLISM; PSYCHOLOGY; SYNAPTIC TRANSMISSION;

COGNITION DISORDERS; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SYNAPTIC TRANSMISSION;

EID: 84942550270     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.68     Document Type: Review

References (78)

1. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007; 64: 1115-1122.
2. Ayesa-Arriola R, Rodriguez-Sanchez JM, Perez-Iglesias R, Gonzalez-Blanch C, Pardo-Garcia G, Tabares-Seisdedos R et al. The relevance of cognitive, clinical and premorbid variables in predicting functional outcome for individuals with first-episode psychosis: a 3 year longitudinal study. Psychiatry Res 2013; 209: 302-308.
3. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
4. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996; 3: 241-253.
5. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
6. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 14: 301-307.
7. Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008; 60: 358-403.
8. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D et al. Ketamineinduced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17: 141-150.
9. Ibrahim HM, Hogg AJ Jr, Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff JH. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry 2000; 157: 1811-1823.
10. Meador-Woodruff JH, Healy DJ. Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 2000; 31: 288-294.
11. Javitt DC, Liederman E, Cienfuegos A, Shelley AM. Panmodal processing imprecision as a basis for dysfunction of transient memory storage systems in schizophrenia. Schizophr Bull 1999; 25: 763-775.
12. Heresco-Levy U, Javitt DC. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 2004; 66: 89-96.
13. Diaz P, Bhaskara S, Dursun SM, Double-blind Deakin B. Placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. J Clin Psychopharmacol 2005; 25: 277-278.
14. Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res 2010; 121: 125-130.
15. Ahmed AO, Bhat IA. Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets. CNS Drugs 2014; 28: 301-318.
16. Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. A randomized, doubleblind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 2010; 13: 451-460.
17. Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-Amino acid oxidase inhibitor. JAMA Psychiatry 2013; 70: 1267-1275.
18. Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008; 33: 465-472.
19. Tsai GE, Lin PY. Strategies to enhance N-methyl-D-Aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-Analysis. Curr Pharm Des 2010; 16: 522-537.
20. Choi KH, Wykes T, Kurtz MM. Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-Analytical investigation of efficacy. Br J Psychiatry 2013; 203: 172-178.
21. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008; 7: 426-437.
22. Imbesi M, Uz T, Manev R, Sharma RP, Manev H. Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors. Neurosci Lett 2008; 447: 134-137.
23. Sassoe-Pognetto M, Cantino D, Panzanelli P, Verdun di Cantogno L, Giustetto M, Margolis FL et al. Presynaptic co-localization of carnosine and glutamate in olfactory neurones. Neuroreport 1993; 5: 7-10.
24. Panzanelli P, Cantino D, Sassoe-Pognetto M. Co-localization of carnosine and glutamate in photoreceptors and bipolar cells of the frog retina. Brain Res 1997; 758: 143-152.
25. Bakardjiev A. Carnosine and beta-Alanine release is stimulated by glutamatergic receptors in cultured rat oligodendrocytes. Glia 1998; 24: 346-351.
26. Smythies J. Redox mechanisms at the glutamate synapse and their significance: a review. Eur J Pharmacol 1999; 370: 1-7.
27. Tamba M, Torreggiani A. Hydroxyl radical scavenging by carnosine and Cu(II)-carnosine complexes: a pulse-radiolysis and spectroscopic study. Int J Radiat Biol 1999; 75: 1177-1188.
28. Hashimoto K. Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opin Ther Targets 2014; 18: 1049-1063.
29. Marx CE, Keefe RS, Buchanan RW, Hamer RM, Kilts JD, Bradford DW et al. Proof-ofconcept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 2009; 34: 1885-1903.
30. Smith CC, Martin SC, Sugunan K, Russek SJ, Gibbs TT, Farb DH. A role for picomolar concentrations of pregnenolone sulfate in synaptic activity-dependent Ca2 + signaling and CREB activation. Mol Pharmacol 2014; 86: 390-398.
31. Moher D, Liberati A, Tetzlaff J, Altman DG. Group P. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-1012.
32. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004; 56: 301-307.
33. Guy W. ECDEU Assessment Manual for Psychopharmacology. NIMH Psychopharmacology Research Branch, Department of Health, Education and Welfare: Rockville, MD, 1976; 218-222.
34. Hirschberg R, Cohen AH, Kopple JD. Effects of keto acid supplements on renal function and histology in azotemic rats fed high-protein diets. Am J Nephrol 1988; 8: 50-56.
35. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
36. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-Analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
37. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-Analysis. Biometrics 2000; 56: 455-463.
38. Higgins BM, Cripps PJ, Baker M, Moore L, Penrose FE, McConnell JF. Effects of body position, imaging plane, and observer on computed tomographic measurements of the lumbosacral intervertebral foraminal area in dogs. Am J Vet Res 2011; 72: 905-917.
39. Cain CK, McCue M, Bello I, Creedon T, Tang DI, Laska E et al. d-Cycloserine augmentation of cognitive remediation in schizophrenia. Schizophr Res 2014; 153: 177-183.
40. Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B et al. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res 2014; 153: 169-176.
41. Schoemaker JH, Jansen WT, Schipper J, Szegedi A. The selective glycine uptake inhibitor Org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. Journal of Clinical Psychopharmacology 2014; 34: 190-198.
42. D'Souza DC, Radhakrishnan R, Perry E, Bhakta S, Singh NM, Yadav R et al. Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. Neuropsychopharmacology 2013; 38: 492-503.
43. Chengappa KN, Turkin SR, DeSanti S, Bowie CR, Brar JS, Schlicht PJ et al. A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia. Schizophr Res 2012; 142: 145-152.
44. Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA et al. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry 2012; 73: e728-e734.
45. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71: 138-149.
46. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I et al. N-Acetyl cysteine as a glutathione precursor for schizophrenia-A double-blind, randomized, placebocontrolled trial. Biol Psychiatry 2008; 64: 361-368.
47. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164: 1593-1602.
48. Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S et al. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res 2004; 71: 239-248.
49. Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001; 21: 484-487.
50. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA et al. A placebocontrolled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56: 21-27.
51. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999; 156: 1822-1825.
52. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44: 1081-1089.
53. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167: 686-693.
54. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. Five-factor model of schizophrenia. Initial validation. J Nerv Ment Dis 1994; 182: 631-638.
55. Ohnuma T, Sakai Y, Maeshima H, Higa M, Hanzawa R, Kitazawa M et al. No correlation between plasma NMDA-related glutamatergic amino acid levels and cognitive function in medicated patients with schizophrenia. Int J Psychiatry Med 2012; 44: 17-27.
56. Bustillo JR, Chen H, Gasparovic C, Mullins P, Caprihan A, Qualls C et al. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry 2011; 69: 19-27.
57. Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X et al. Elevated prefrontal cortex gamma-Aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2012; 69: 449-459.
58. Kraguljac NV, White DM, Reid MA, Lahti AC. Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry 2013; 70: 1294-1302.
59. Ohrmann P, Siegmund A, Suslow T, Pedersen A, Spitzberg K, Kersting A et al. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J Psychiatr Res 2007; 41: 625-634.
60. Reid MA, Kraguljac NV, Avsar KB, White DM, den Hollander JA, Lahti AC. Proton magnetic resonance spectroscopy of the + in schizophrenia. Schizophr Res 2013; 147: 348-354.
61. Rusch N, Tebartz van Elst L, Valerius G, Buchert M, Thiel T, Ebert D et al. Neurochemical and structural correlates of executive dysfunction in schizophrenia. Schizophr Res 2008; 99: 155-163.
62. Shirayama Y, Obata T, Matsuzawa D, Nonaka H, Kanazawa Y, Yoshitome E et al. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. Neuroimage 2010; 49: 2783-2790.
63. Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A et al. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res 2014; 152: 325-332.
64. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005; 162: 495-506.
65. Torgalsboen AK, Mohn C, Rishovd Rund B. Neurocognitive predictors of remission of symptoms and social and role functioning in the early course of first-episode schizophrenia. Psychiatry Res 2014; 216: 1-5.
66. Huganir RL, Nicoll RA. AMPARs and synaptic plasticity: the last 25 years. Neuron 2013; 80: 704-717.
67. MacDonald ML, Ding Y, Newman J, Hemby S, Penzes P, Lewis DA et al. Altered glutamate protein co-expression network topology linked to spine loss in the auditory cortex of schizophrenia. Biol Psychiatry 2015; 77: 959-968.
68. Wu Y, Arai AC, Rumbaugh G, Srivastava AK, Turner G, Hayashi T et al. Mutations in ionotropic AMPA receptor 3 alter channel properties and are associated withmoderate cognitive impairment in humans. Proc Natl Acad Sci USA 2007; 104: 18163-18168.
69. Olney JW, Farber NB. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 1995; 13: 335-345.
70. Takahata R, Moghaddam B. Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 2003; 28: 1117-1124.
71. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921-2927.
72. Jackson ME, Homayoun H, Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci USA 2004; 101: 8467-8472.
73. Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 2013; 263: 367-377.
74. Carone FA, Ganote CE. D-serine nephrotoxicity. The nature of proteinuria, glucosuria, and aminoaciduria in acute tubular necrosis. Arch Pathol 1975; 99: 658-662.
75. Krysta K, Murawiec S, Klasik A, Wiglusz MS, Krupka-Matuszczyk I. Sex-specific differences in cognitive functioning among schizophrenic patients. Psychiatr Danub 2013; 25: S244-S246.
76. Hafner H, Maurer K, Loffler W, an der Heiden W, Hambrecht M, Schultze-Lutter F. Modeling the early course of schizophrenia. Schizophr Bull 2003; 29: 325-340.
77. Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M. Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol 2012; 165: 1543-1555.
78. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004; 9: 979.